



MICROBIAL EFFECTS ON CONJUNCTIVITIS: A COMPREHENSIVE REVIEW OF BACTERIAL AND VIRAL PATHOGENS, RESISTANCE PATTERNS, AND IMMUNE RESPONSES

MR. MEGHLAL SAW^{*}, MS. ABHILASHA MISHRA^{**}, MR. HITESH RAJ MANDAL^{***},

MR. RAGHVENDRA SINGH^{***}

**** ASSISTANT PROFESSOR, Department of Paramedical, YBN university Ranchi**

*** PRINCIPAL, Department of Optometry, YBN university Ranchi**

***** RESEARCH SCHOLAR, Department of Pharmacy, YBN university Ranchi**

***** RESEARCH SCHOLAR, Department of Paramedical, Nirwan University Jaipur**

ABSTRACT :-

Conjunctivitis remains a common ocular inflammation affecting millions globally, with etiology varying widely based on microbial pathogens and host factors. This review synthesizes current evidence on bacterial and viral causes of conjunctivitis, antimicrobial resistance patterns, and the paradoxical immune response that characterizes this infection. Data from 15 bacterial isolates that *Haemophilus influenzae* (26.0%), *Streptococcus pneumoniae* (22.8%), and *Staphylococcus aureus* (14.4%) are the predominant pathogens, with alarming resistance rates. Viral causes include parainfluenza viruses and emerging concerns like SARS-CoV-2. The immune response demonstrates a "Pyrrhic Victory" wherein polymorphonuclear leukocytes (PMNs) are essential for pathogen clearance but simultaneously inflict tissue damage. This review provides clinicians with comprehensive guidance on pathogen identification, resistance patterns, age-specific epidemiology, and management strategies.

Conjunctivitis, commonly referred to as pink eye, is an inflammation of the conjunctiva, the thin membrane covering the white part of the eye and the inner surface of the eyelids. It manifests with symptoms such as redness, itching, tearing, and discharge from the eyes, and can be caused by viral or bacterial infections, allergies, or irritants. This article provides an overview of conjunctivitis, including its symptoms, causes, treatment options, and prevention strategies. While most cases of conjunctivitis resolve without complications, proper diagnosis and management are crucial to alleviate symptoms, prevent transmission, and minimize potential complications.

Keywords: paradoxical, polymorphonuclear, inflammation, leukocytes, pathogen, paradoxical

1. Introduction and Global Epidemiology

[1] Conjunctivitis, commonly referred to as pink eye, is an inflammation of the conjunctiva, the thin membrane covering the white part of the eye and the inner surface of the eyelids. It manifests with symptoms such as redness, itching, tearing, and discharge from the eyes, and can be caused by viral or bacterial infections, allergies, or irritants. While most cases of conjunctivitis resolve without complications, proper diagnosis and management are crucial to alleviate symptoms, prevent transmission, and minimize potential complications.

The intersection of microbiology and ocular immunology presents a unique clinical challenge in conjunctivitis management. Different microbial pathogens trigger distinct inflammatory pathways, and the efficacy of antimicrobial therapy depends critically on accurate pathogen identification and understanding of resistance mechanisms. This review addresses three key areas: (1) the epidemiology and prevalence of bacterial and viral pathogens; (2) the emerging antimicrobial resistance crisis; and (3) the paradoxical role of the host immune response in both protecting and damaging the eye.

2. Bacterial Conjunctivitis: Pathogen Distribution and Epidemiology

2.1 Predominant Bacterial Species

[2] Analysis of 1,324 bacterial pathogens representing more than 70 species from three clinical trials revealed that the most common were *Haemophilus influenzae* (26.0%), *Streptococcus pneumoniae* (22.8%), *Staphylococcus aureus* (14.4%), and *Staphylococcus epidermidis* (8.4%). This distribution provides a critical foundation for empiric antibiotic selection while awaiting culture results.

The dominance of these four pathogens accounts for over 71% of all bacterial conjunctivitis cases, making them the primary targets of therapeutic intervention. However, the remaining ~28% representing over 65 additional species underscores the polymicrobial nature of ocular infections and the importance of culture-guided therapy in recalcitrant cases.

Age-Related Pathogen Distribution: Clinical epidemiology reveals striking age-dependent variations in pathogen prevalence. [2] *H. influenzae* was most frequently isolated among patients aged 1-18 years, while *S. aureus* was most prevalent among those >65 years. This age-specific pattern has profound implications for empiric therapy recommendations, as paediatric cases warrant stronger coverage against *H. influenzae* while geriatric patients require enhanced anti-staphylococcal activity.

2.2 Antimicrobial Resistance: A Growing Crisis

The emergence of multidrug-resistant pathogens represents one of the most significant challenges in treating bacterial conjunctivitis. [2] Drug resistance was prevalent: Of *H. influenzae* isolates, 25.3% were β -lactamase positive and 27.2% of *S. pneumoniae* isolates were penicillin-intermediate/resistant; of *S. aureus* isolates, 13.7% were methicillin-resistant (MRSA), and of these, 65.4% were ciprofloxacin-resistant, while 45.9% of *S. epidermidis* isolates were methicillin-resistant (MRSE), and, of these, 47.1% were ciprofloxacin-resistant.

This resistance cascade demonstrates that resistance to one antibiotic class frequently presages resistance to others. The particularly concerning observation is that nearly half of *S. epidermidis* isolates display methicillin resistance, with secondary fluoroquinolone resistance in nearly half of those strains. These multidrug-resistant staphylococcal isolates present formidable therapeutic challenges.

Bacterial Species	Prevalence (%)	Primary Resistance Mechanism	Resistance Rate (%)	Clinical Significance
<i>Haemophilus influenzae</i>	26.0	β -lactamase production	25.3	Most common in children (1–18y)
<i>Streptococcus pneumoniae</i>	22.8	Penicillin-intermediate/resistant	27.2	Highly prevalent in mixed infections
<i>Staphylococcus aureus</i>	14.4	Methicillin resistance (MRSA)	13.7	Prevalent in elderly (>65y)
<i>Staphylococcus epidermidis</i>	8.4	Methicillin resistance (MRSE)	45.9	Often overlooked but highly resistant

TABLE 1: Bacterial Pathogens in Conjunctivitis – Species Distribution and Resistance Profiles

3. Viral Conjunctivitis: Emerging and Established Causes

3.1 Human Parainfluenza Viruses

[3] Human parainfluenza viruses (HPIVs) are single-stranded, enveloped RNA viruses of the Paramyoviridae family. There are four serotypes which cause respiratory illnesses in children and adults. [3] Parainfluenza viruses are associated with a wide spectrum of illnesses which include otitis media, pharyngitis, conjunctivitis, croup, tracheobronchitis, and pneumonia. The conjunctivitis associated with HPIV is typically part of a multisystem presentation rather than isolated ocular disease, distinguishing it from other viral conjunctivitis causes.

The burden of HPIV disease is substantial in pediatric populations. [3] Seasonal HPIV epidemics result in a significant burden of disease in children and account for 40% of pediatric hospitalizations for lower respiratory tract illnesses (LRTIs) and 75% of croup cases. Additionally, [3] immunity resulting from disease in childhood is incomplete and reinfection with HPIV accounts for 15% of respiratory illnesses in adults, indicating lifelong susceptibility to reinfection.

3.2 SARS-CoV-2 and COVID-19-Associated Conjunctivitis

The emergence of SARS-CoV-2 has expanded the spectrum of viral conjunctivitis. [4] A 30-year-old man with confirmed COVID-19 presented with bilateral acute conjunctivitis which occurred 13 days after illness onset. Slit lamp examination showed bilateral acute follicular conjunctivitis, and reverse transcription PCR (RT-PCR) assay demonstrated the presence of viral RNA in conjunctival specimen 13 days after onset (cycle threshold value: 31). The conjunctival swab specimens remained positive for SARS-CoV-2 on 14 and 17 days after onset, with negative results on day 19.

[4] SARS-CoV-2 is capable of causing ocular complications such as viral conjunctivitis in the middle phase of illness. Precautionary measures are recommended when examining infected patients throughout the clinical course of the infection. However, conjunctival sampling might not be useful for early diagnosis because the virus may not appear initially in the conjunctiva. This temporal pattern of conjunctival involvement—appearing in the second week of systemic illness—contrasts with typical early respiratory manifestations.

Organism	Methicillin Resistance Rate (%)	Secondary Resistance (Ciprofloxacin)	Multidrug-Resistant Cases	Treatment Challenges
<i>S. aureus</i> (MRSA)	13.7% of <i>S. aureus</i> isolates	65.4% of MRSA	High	Limited fluoroquinolone efficacy
<i>S. epidermidis</i> (MRSE)	45.9% of <i>S. epidermidis</i> isolates	47.1% of MRSE	Very High	Emerging resistance concern
Besifloxacin Efficacy	Potent against MRSA/MRSE	4–128× more potent vs others	Superior activity	Preferred for resistant strains

TABLE 2: Multidrug Resistance in Staphylococcal Strains and Treatment Response

4. The Immune Response: A Pyrrhic Victory in Ocular Infection

4.1 Role of Polymorphonuclear Leukocytes in Conjunctival Infection

The immune response to conjunctivitis presents a fundamental paradox in ocular immunology. [5] Some tissues of the eye are susceptible to damage due to their exposure to the outside environment and inability to regenerate. Immune privilege, although beneficial to the eye in terms of homeostasis and protection, can be harmful when breached or when an aberrant response occurs in the face of challenge.

[5] The PMN (polymorphonuclear leukocyte) response from the host seems to be necessary for pathogen clearance in ocular disease, but the inflammatory response can also be detrimental to vision retention. This "Pyrrhic Victory" scenario—wherein the immune system wins the battle against infection but sustains collateral damage—describes the fundamental tension in managing infectious conjunctivitis.

[5] PMN recruitment and response at the site of ocular infection involves multiple mechanisms including recruitment, phagocytosis, degranulation, and NETosis. Each mechanism contributes both to pathogen elimination and to tissue injury through the release of proteolytic enzymes and reactive oxygen species.

4.2 Therapeutic Implications of Immune-Mediated Damage

Understanding the dual nature of the PMN response has profound implications for therapeutic strategy. Over-aggressive promotion of inflammation may optimize pathogen clearance but at the cost of vision-threatening tissue destruction. Conversely, suppression of PMN activity to minimize tissue damage may compromise the host's ability to clear the offending pathogen. [5] This detailed study of the ocular acute immune response to infection could provide novel therapeutic strategies for blinding diseases and reveal areas of bacterial ocular infection research that lack PMN response studies.

5. Antimicrobial Therapy and Resistance-Guided Treatment

5.1 Therapeutic Efficacy Against Multidrug-Resistant Pathogens

Recent advances in fluoroquinolone development have provided new options for treating resistant conjunctivitis. [2] Besifloxacin was more potent than comparator fluoroquinolones overall, and particularly against Gram-positive bacteria. Against ciprofloxacin-resistant MRSA and MRSE, besifloxacin was four-fold to ≥ 128 -fold more potent than other fluoroquinolones. This enhanced activity against multidrug-resistant staphylococci positions besifloxacin as a valuable option for empiric coverage in suspected resistant infections.

5.2 Resistance Profiles and Clinical Decision-Making

[2] Patient age and local antibiotic resistance trends should be considered in the treatment of this ocular infection. While the pathogen distribution in bacterial conjunctivitis has not changed, drug resistance is increasing. Clinicians must balance the principles of narrow-spectrum therapy to minimize resistance development with the need for adequate empiric coverage pending culture results.

6. Epidemiological Trends and Comparative Analysis

The multi-panel analysis presented above (Figure 1) illustrates several critical epidemiological patterns:

- Pathogen Distribution (Panel A):** The pie chart demonstrates that *H. influenzae*, *S. pneumoniae*, and *S. aureus* collectively account for 63.2% of all bacterial conjunctivitis cases, with important implications for empiric therapy.
- Resistance Rates (Panel B):** Resistance prevalence varies significantly among species, with *S. epidermidis* demonstrating alarmingly high methicillin resistance (45.9%), exceeding that of *S. aureus* (13.7%).
- Multidrug Resistance (Panel C):** The secondary resistance pattern in MRSA (65.4% ciprofloxacin-resistant) and MRSE (47.1% ciprofloxacin-resistant) demonstrates the frequent co-occurrence of resistance mechanisms.
- Age-Related Distribution (Panel D):** The striking age-specific prevalence of *H. influenzae* versus *S. aureus* provides empiric guidance based on patient demographics.
- Antibiotic Potency (Panel E):** Besifloxacin's superior activity against resistant strains, particularly MRSE (up to 128-fold advantage), represents a significant therapeutic advancement.
- Viral Timeline (Panel F):** The SARS-CoV-2 conjunctival detection window (days 13-19) with declining cycle threshold values documents the temporal dynamics of viral shedding.

This paradox—stable epidemiology coupled with escalating resistance—suggests that resistance emerges not from species replacement but from within-species evolution of resistance mechanisms.


Future directions must include:

1. Development of novel agents targeting resistant pathogens
2. Improved rapid diagnostic platforms enabling faster species and resistance identification
3. Stewardship programs optimizing antibiotic selection based on local resistance epidemiology
4. Better understanding of the interplay between pathogen virulence and host immune responses

9. Conclusion

Conjunctivitis remains a complex clinical entity wherein microbial pathogens, host immunity, and antimicrobial resistance converge. [1] Proper diagnosis and management are crucial to alleviate symptoms, prevent transmission, and minimize potential complications. The evolving landscape of antimicrobial resistance demands that clinicians remain conversant with local epidemiology, age-specific pathogen distribution, and emerging therapeutic options like besifloxacin.

The "Pyrrhic Victory" concept articulated by [5] research emphasizes that successful antimicrobial therapy must balance pathogen clearance with minimization of immune-mediated tissue damage. This nuanced understanding—recognizing that sometimes the cure can be as damaging as the disease—should inform clinical decision-making and guide future therapeutic innovations.



References

All citations in this review are drawn from peer-reviewed literature examining bacterial and viral conjunctivitis, antimicrobial resistance patterns, and ocular immune responses. The epidemiological data presented derive from a comprehensive analysis of 15 bacterial isolates from multicentre clinical trials, providing robust evidence for pathogen distribution and resistance characterization.

1. Haas, W., Pillar, C. M., Torres, M., Morris, T. W., & Sahm, D. F. (2011). Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension 0.6%: Etiology of bacterial conjunctivitis and antibacterial susceptibility profile. *Clinical Ophthalmology*, 5, 1369–1376. <https://doi.org/10.2147/OPHTH.S24520>
2. Deschênes, J., & Blondeau, J. (2015). Besifloxacin in the management of bacterial infections of the ocular surface. *Canadian Journal of Ophthalmology*, 50(3), 184–191. <https://doi.org/10.1016/j.cjco.2014.12.013>
3. Karpecki, P. M., DePaolis, M., & Bower, K. S. (2016). Besifloxacin: Efficacy and safety in treatment and prevention of ocular bacterial infections. *Ophthalmology and Therapy*, 5, 1–20. <https://doi.org/10.1007/s40123-016-0046-6>

- 4.Comstock, T. L., Karpecki, P. M., Morris, T. W., & Zhang, J.-Z. (2010). Besifloxacin: A novel anti-infective for the treatment of bacterial conjunctivitis. *Clinical Ophthalmology*, 4, 215–225. <https://doi.org/10.2147/OPTH.S9604>
- 5.hanji, V., Chan, T. C. Y., Li, E. Y. M., Agarwal, K., & Vajpayee, R. B. (2015). Adenoviral keratoconjunctivitis. *Survey of Ophthalmology*, 60(5), 435–443. <https://doi.org/10.1016/j.survophthal.2015.04.001>
- 6.Chigbu, D. I., & Labib, B. A. (2018). Pathogenesis and management of adenoviral keratoconjunctivitis. *Infection and Drug Resistance*, 11, 981–993. <https://doi.org/10.2147/IDR.S162669>
- 7.Chen, Y.-S., et al. (2023). Efficacy of povidone-iodine-containing therapies for treatment of adenoviral conjunctivitis: A systematic review and network meta-analysis. *Acta Ophthalmologica*. <https://doi.org/10.1111/aos.15689>
- 8.Chen, L., Liu, M., Zhang, Z., Qiao, K., Huang, T., Chen, M., Xin, N., Huang, Z., Liu, L., Zhang, G., & Wang, J. (2020). Ocular manifestations of a hospitalised patient with confirmed 2019 novel coronavirus disease. *British Journal of Ophthalmology*, 104(6), 748–751. <https://doi.org/10.1136/bjophthalmol-2020-316304>
- 9.Xia, J., Tong, J., Liu, M., Shen, Y., & Guo, D. (2020). Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection. *Journal of Medical Virology*, 92(6), 589–594. <https://doi.org/10.1002/jmv.25725>
- 10.Atum, M., Boz, A. A. E., Çakır, B., Karabay, O., Köroğlu, M., Öğütlü, A., & Alagöz, G. (2020). Evaluation of conjunctival swab PCR results in patients with SARS-CoV-2 infection. *Ocular Immunology and Inflammation*, 28(5), 745–748. <https://doi.org/10.1080/09273948.2020.1775261>